Celldex Therapeutics CLDX Business Segments — Labor And Related Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's business segments — labor and related expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Celldex Therapeutics's business segments — labor and related expense?
- Celldex Therapeutics (CLDX) reported business segments — labor and related expense of $15.57M in Q1 2026.
- How has Celldex Therapeutics's business segments — labor and related expense changed year-over-year?
- Celldex Therapeutics's business segments — labor and related expense increased by 14.5% year-over-year, from $13.6M to $15.57M.
- What does business segments — labor and related expense mean?
- This metric captures the total compensation and benefits costs associated with the workforce dedicated to the company's primary business segment. It reflects the investment in human capital required to drive research, development, and operational objectives. Analyzing this expense helps investors understand the company's labor intensity and its ability to attract and retain specialized scientific talent.